Alumis closes $259M series C in year's largest private biotech fundraise yet gmasson Tue, 03/05/2024 - 17:22.: Alumis has reeled in an eye-watering $259 million series C financing that will support a pipeline of oral therapies designed to tackle immune dysfunction and help launch a phase 3 psoriasis trial for lead asset ESK-001. It marks the biggest haul for a private biotech so far in 2024, according to Fierce Biotech’s Fundraising Tracker.